BACKGROUND: Patients with severe hemophilia A and factor VIII inhibitors are at increased risk for serious bleeding complications and progression to end-stage joint disease. Effective strategies to prevent bleeding in such patients have not yet been established. METHODS: We enrolled patients with hemophilia A who were older than 2 years of age, had high-titer inhibitors, and used concentrates known as bypassing agents for bleeding in a prospective, randomized, crossover study comparing 6 months of anti-inhibitor coagulant complex (AICC), infused prophylactically at a target dose of 85 U per kilogram of body weight (±15%) on 3 nonconsecutive days per week, with 6 months of on-demand therapy (AICC at a target dose of 85 U per kilogram [±15%] used for bleeding episodes). The two treatment periods were separated by a 3-month washout period, during which patients received on-demand therapy for bleeding. The primary outcome was the number of bleeding episodes during each 6-month treatment period. RESULTS: Thirty-four patients underwent randomization; 26 patients completed both treatment periods and could be evaluated per protocol for the efficacy analysis. As compared with on-demand therapy, prophylaxis was associated with a 62% reduction in all bleeding episodes (P<0.001), a 61% reduction in hemarthroses (P<0.001), and a 72% reduction in target-joint bleeding (≥3 hemarthroses in a single joint during a 6-month treatment period) (P<0.001). Thirty-three randomly assigned patients received at least one infusion of the study drug and were evaluated for safety. One patient had an allergic reaction to the study drug. CONCLUSIONS: AICC prophylaxis at the dosage evaluated significantly and safely decreased the frequency of joint and other bleeding events in patients with severe hemophilia A and factor VIII inhibitors (Funded by Baxter BioScience; Pro-FEIBA ClinicalTrials.gov number, NCT00221195.)
Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors / C. Leissinger, A. Gringeri, B. Antmen, E. Berntorp, C. Biasoli, S. Carpenter, P. Cortesi, H. Jo, K. Kavakli, R. Lassila, M. Morfini, C. Négrier, A. Rocino, W. Schramm, M. Serban, M. V. Uscatescu, J. Windyga, B. Zülfikar, L. Mantovani. - In: NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - 365:18(2011 Nov 03), pp. 1684-1692.
|Titolo:||Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors|
|Parole Chiave:||Iinhibitor ; prophylaxis ; bleeding events ; hemophilia|
|Settore Scientifico Disciplinare:||Settore MED/09 - Medicina Interna|
|Data di pubblicazione:||3-nov-2011|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1056/NEJMoa1104435|
|Appare nelle tipologie:||01 - Articolo su periodico|